CARPINTERIA, Calif.--(BUSINESS WIRE)--Celerus Diagnostics, the rapid cancer diagnostics company, today announced the completion of $5 million in financing by private investors.
“We’re delighted with the first closing of our Series C financing,” said Dave Gross, newly named Chief Executive Officer of Celerus Diagnostics. “With this additional investment, we will further address market demand for rapid IHC (immunohistochemistry) testing and accelerate the commercialization of our onboard heating solution for the Celerus Wave.”
The Celerus Wave System is the first and only solution to deliver precise, standardized histology and cytology results in 15 minutes. Intra-operative frozen tissue sections now undergo IHC staining regularly using the Wave System. At its core, patented Dynamic Replenishment Technology utilizes breakthroughs in hydrodynamics and biochemistry to accelerate reactions in the laboratory.
“This allows for the decentralization of testing and moves results closer to the patient for faster decision making,” said Gross. “By addressing the unmet needs of the anatomic pathology laboratory, the Celerus Wave provides real-time solutions for cancer patient management.”
The Celerus Wave System is currently in use at numerous hospitals and reference laboratories across the country.
About Celerus Diagnostics Founded in 2004 in Santa Barbara, California, Celerus Diagnostics develops innovative solutions to enhance the diagnostic capabilities of the anatomic pathology laboratory, provide clinicians with rapid, reliable, actionable diagnostic information, and advance patient care. The first Celerus Wave Systems were installed in North America and Europe in 2008.
